Concordia Healthcare Corp. T.CXR.R

RE:RE:RE:RE:RE:F U G L Y

[Select11]

The best thing is how much they tout new products.  Fade that hope.  Bring on the analysts.

Iattice wrote: a critical word was omitted ...  that is ** without** them seeing the full legal effect of the new Pricing Bill in the UK

Iattice wrote: ???  The Net Loss was $78.8 million.  They continue to bleed and wouldn't answer basic questions (like from Meihm when he asked how much are you paying in the voluntary generics scheme - 7% or 1%?)  And no guidance this time either which means no confidence that they can meet their debt obligation.   International revs decreased almost ~8% and that is the int'l segment  seeing the full legal effect of the new UK Bill (which if you listened to Oberman, won't affect them until 2018).  If you are long here, you need your head examined.

Restructuring is the only option for them.  

Imedb36 wrote:

Mmm read all of information !

Reported Adjusted EBITDA¹ of $84.2 million, compared to  $80.5 million in the fourth quarter of 2016. 4m$ better than last quarter -- > the compagny has stabilized

the Company launched one new product in an IMS  of $30 million. IMS value anticipated to be in excess of $100 million

In addition, the Company has eight products under active development that it anticipates will launch in the next three to five years.  IMS-measured market value expected to be in excess of $1 billion. 

Finally, Concordia has identified up to 21 additional products for future development with its network of external partners. If launched, these products are anticipated to compete in estimated current IMS measured markets that are expected to be worth hundreds of millions more.